07:00 , Jul 23, 2012 |  BioCentury  |  Product Development

Debio's dual deal

Debiopharm Group has been stocking up its early stage cancer pipeline with assets it believes have best-in-class potential, the latest being a preclinical dual tyrosine kinase inhibitor from Ascepion Pharmaceuticals Inc. The deal is the...
07:00 , Jun 25, 2012 |  BC Week In Review  |  Company News

Ascepion, Debiopharm deal

Ascepion granted Debiopharm exclusive, worldwide rights to develop and commercialize Debio 1144 (formerly ASP-08126 ). The oral small molecule that inhibits several tyrosine kinases is in preclinical testing for cancer, with clinical trials slated to...
01:48 , Jun 19, 2012 |  BC Extra  |  Company News

Debiopharm, Ascepion in cancer deal

Ascepion Pharmaceuticals Inc. (Suzhou, China) granted Debiopharm Group (Lausanne, Switzerland) exclusive, worldwide rights to develop and commercialize Debio 1144 (formerly ASP-08126). The oral small molecule that inhibits several tyrosine kinases is in preclinical testing for...